DBV Technologies

Corporate Details

ISIN(s):

FR0010417345 (+3 more)

LEI:

969500PVBQFWQKVDMD80

Country:

France

Address:

107 AVENUE DE LA REPUBLIQUE, 92320 CHATILLON

Website:

https://www.dbv-technologies.com/

Sector:

Health Care

Industry:

Biotechnology

Description

DBV Technologies is developing Viaskin™, an investigational proprietary technology platform with broad potential clinical applications. Viaskin is based on epicutaneous immunotherapy, or EPIT™, a method of delivering biologically active compounds to the immune system through intact skin. With this new class of patch-based, non-invasive product candidates, the Company is dedicated to safely transforming the care of food-allergic patients. DBV’s food allergy programs include ongoing clinical trials of Viaskin™ Peanut in children. In addition to food allergies, Viaskin technology is also being investigated as a treatment option for other immunological disorders. Additional applications for Viaskin, such as use as a diagnostic tool for non-IgE-mediated milk allergy or as a non-invasive method for delivering vaccines against certain diseases, are also being investigated. DBV Technologies has global headquarters in Montrouge, France, and North American operations in Summit, NJ.